Exchange: NASDAQ Sector: Healthcare Industry: Medical Instruments & Supplies
-6.01% $2.19
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 23.09 mill |
EPS: | -0.150 |
P/E: | -14.60 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 10.54 mill |
Avg Daily Volume: | 0.0206 mill |
RATING 2024-03-28 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -14.60 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.44x |
Company: PE -14.60 | industry: PE 33.06 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 1.949 - 2.43 ( +/- 11.00%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Wexford Capital Lp | Sell | 91 463 | Common Stock |
2024-03-13 | Amron Arthur H | Buy | 91 463 | Common stock |
2024-03-12 | Amron Arthur H | Buy | 7 000 | Common stock |
2023-12-13 | Spandow Oliver J. | Buy | 14 294 | Common Stock |
2023-12-13 | Lask Alisa | Buy | 9 291 | Common Stock |
INSIDER POWER |
---|
4.17 |
Last 97 transactions |
Buy: 1 485 864 | Sell: 673 582 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.19 (-6.01% ) |
Volume | 0.0032 mill |
Avg. Vol. | 0.0206 mill |
% of Avg. Vol | 15.38 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.